Page 154 - Case Lab Case Analysis
P. 154
PROBLEM: PRICING
Mylan’s revenue
increase was aided
when Sanofi's
competing product
was recalled in
November 2015 and
further when Teva's
generic competitor
was rejected by the
FDA in March 2016.
